My proposal now is to test a vaccine first on people who have been infected, and if you show some efficacy at this level, you might be able to go further to study uninfected people in a population with a high rate of infection.

The idea of the live-virus vaccine is to produce in a continuous way some viral antigens.

Our goal is not to completely eradicate the infection - that would be very difficult - but to produce a vaccine that will prevent not infection but disease. I think this is more possible.

I am very puzzled by the fact that young people are getting infected again. They don't take precautions despite an enormous amount of information. It's like riding a race car at 200 kilometers an hour. Some people like the risk.

It's clear that prevention will never be sufficient. That's why we need a vaccine that will be safe.

We are working with a biotech company, Calypte, which has designed a urine test for the HIV antibody.